BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is being compared against standard chemotherapy drugs, doxorubicin or paclitaxel, ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...